Programs

  • DeltaRex-G Clinical Studies

    THE AVENIFOUNDATION REPORTED THE PERFORMANCE OF TWO CLINICAL STUDIES:1. Compassionate Use of Intravenous DeltaRex-G Tumor-Targeted Retrovector Bearing a Cytocidal Dominant Negative Cyclin G1 Inhibitor for Advanced Sarcoma, Pancreatic Cancer, Non-small Cell Lung Cancer, Breast Cancer, Cholangiocarcinoma, Basal Cell Carcinoma (Single Use INDs)2. Blessed: Expanded Access for DeltaRex-G for Advanced Pancreatic Cancer and Sarcoma for an Intermediate Size Population (NCT04091295)INTERIM RESULTS SHOWED THE FOLLOWING:Eighteen patients were enrolled, 10 sarcoma, 2 pancreatic adenocarcinoma, 1 non-small cell lung cancer, 2 breast carcinoma, 1 prostate cancer, 1 cholangiocarcinoma and 1 basal cell carcinoma. Fifteen patients were enrolled in Study 1 single patient use IND, 3 patients were enrolled in Study 2. Two patients were initially enrolled in Study 2, and later enrolled in Study 1. Twelve of 18 enrolled patients were treated with DeltaRex-G monotherapy or in combination with FDA approved cancer therapies. Six of 18 enrolled patients are alive, 2 with breast cancer are alive in complete remission, 2 with sarcoma are alive with stable disease, 1with basal cell carcinoma is alive with partial response and 1 with sarcoma is alive with progressive disease. Three patients died of progressive disease before receiving DeltaRex-G. Two patients withdrew without receiving DeltaRex-G.
    Geographies
    Not indicated
    Dates
    Jan 1, 2022 – Dec 31, 2022
    Source
    990
    No causes provided
    No populations provided
    –
    $171.8K